Home › Companies › Allogene Therapeutics, Inc. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Allogene Therapeutics, Inc.’s Form 8-K, filed June 23, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 18, 2025: 5 items on Allogene Therapeutics, Inc.’s Form 8-K, filed June 23, 2025: 3 elected · 2 approved.
Notable dissent: 1 director (16.5% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Allogene Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Allogene Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Elizabeth Barrett | 131,435,760 | -- | -- | 25,929,654 | 33,512,034 | 84% | Elected | — |
| Elect Director: Arie Belldegrun, M.D. | 150,891,245 | -- | -- | 6,474,169 | 33,512,034 | 96% | Elected | — |
| Elect Director: David Chang, M.D., Ph.D. | 153,721,017 | -- | -- | 3,644,397 | 33,512,034 | 98% | Elected | — |
| 2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers | 139,947,868 | 14,233,309 | 3,184,237 | -- | 33,512,034 | 91% | Approved | — |
| 3. Ratification of the Selection of Independent Registered Public Accounting Firm | 190,111,256 | 414,604 | 351,588 | -- | 0 | 99.8% | Approved | — |
Source: Allogene Therapeutics, Inc., Form 8-K, filed with the SEC on June 23, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
141 asset managers disclosed a vote on at least one Allogene Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 2 wordings of this item as funds reported it.
96% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Arie Belldegrun, M.D.
Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Arie Belldegrun, M.D.”): 150,891,245 for, 6,474,169 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 26,989,897 for, 1,883,941 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 12,265,330 | 0 | 0 | 0 | For |
| Vanguard | 5,033,780 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,096,572 | 0 | 0 | 0 | For |
| BlackRock | 2,062,716 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 867,250 | Withhold |
| JPMorgan | 682,959 | 0 | 0 | 0 | For |
| Equitable | 214,715 | 0 | 0 | 222,038 | Mixed |
| Charles Schwab | 428,818 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 273,875 | 0 | 0 | 0 | For |
| Fidelity | 263,240 | 0 | 0 | 0 | For |
| Lincoln Financial | 137,536 | 0 | 0 | 111,015 | Mixed |
| Global X | 241,564 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| Zacks Trust | 137,161 | 0 | 0 | 0 | For |
| State Street | 45 | 0 | 0 | 120,405 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 96,500 | Withhold |
| John Hancock | 81,376 | 0 | 0 | 10,737 | Mixed |
| Northern Trust | 76,818 | 0 | 0 | 0 | For |
| Pacific Life | 68,912 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 0 | 68,858 | Withhold |
| ETFis Series Trust I | 0 | 0 | 0 | 60,814 | Withhold |
| Bridge Builder Trust | 57,984 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 44,900 | Withhold |
| RBB FUND, INC. | 33,621 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: David Chang, M.D., Ph.D.
Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: David Chang, M.D., Ph.D.”): 153,721,017 for, 3,644,397 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 28,301,714 for, 572,124 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 12,265,330 | 0 | 0 | 0 | For |
| Vanguard | 5,033,780 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,096,572 | 0 | 0 | 0 | For |
| BlackRock | 2,062,716 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 867,250 | 0 | 0 | 0 | For |
| JPMorgan | 682,959 | 0 | 0 | 0 | For |
| Equitable | 436,753 | 0 | 0 | 0 | For |
| Charles Schwab | 428,818 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 273,875 | 0 | 0 | 0 | For |
| Fidelity | 263,240 | 0 | 0 | 0 | For |
| Lincoln Financial | 231,336 | 0 | 0 | 17,215 | Mixed |
| Global X | 241,564 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| Zacks Trust | 137,161 | 0 | 0 | 0 | For |
| State Street | 120,420 | 0 | 0 | 30 | For |
| AIG/SunAmerica | 0 | 0 | 0 | 96,500 | Withhold |
| John Hancock | 81,376 | 0 | 0 | 10,737 | Mixed |
| Northern Trust | 76,818 | 0 | 0 | 0 | For |
| Pacific Life | 68,912 | 0 | 0 | 0 | For |
| ETF Series Solutions | 0 | 0 | 0 | 68,858 | Withhold |
| ETFis Series Trust I | 0 | 0 | 0 | 60,814 | Withhold |
| Bridge Builder Trust | 57,984 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 44,900 | Withhold |
| RBB FUND, INC. | 33,621 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
84% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Elizabeth Barrett
Allogene Therapeutics, Inc.’s own tally for this item (“Elect Director: Elizabeth Barrett”): 131,435,760 for, 25,929,654 withheld, per its Form 8-K filed June 23, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the three persons listed below as Class I Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 11,152,293 for, 17,721,545 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 0 | 0 | 12,265,330 | Withhold |
| Vanguard | 2,964,570 | 0 | 0 | 2,069,210 | Mixed |
| T. Rowe Price | 3,096,572 | 0 | 0 | 0 | For |
| BlackRock | 1,681,891 | 0 | 0 | 380,825 | Mixed |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 867,250 | Withhold |
| JPMorgan | 682,959 | 0 | 0 | 0 | For |
| Equitable | 55,559 | 0 | 0 | 381,194 | Mixed |
| Charles Schwab | 0 | 0 | 0 | 428,818 | Withhold |
| Columbia Threadneedle | 273,875 | 0 | 0 | 0 | For |
| Fidelity | 217,218 | 0 | 0 | 46,022 | Mixed |
| Lincoln Financial | 137,536 | 0 | 0 | 111,015 | Mixed |
| Global X | 0 | 0 | 0 | 241,564 | Withhold |
| Delaware/Macquarie | 0 | 0 | 0 | 146,779 | Withhold |
| Zacks Trust | 137,161 | 0 | 0 | 0 | For |
| State Street | 45 | 0 | 0 | 120,405 | Withhold |
| AIG/SunAmerica | 0 | 0 | 0 | 96,500 | Withhold |
| John Hancock | 81,376 | 0 | 0 | 10,737 | Mixed |
| Northern Trust | 0 | 0 | 0 | 76,818 | Withhold |
| Pacific Life | 0 | 0 | 0 | 68,912 | Withhold |
| ETF Series Solutions | 0 | 0 | 0 | 68,858 | Withhold |
| ETFis Series Trust I | 0 | 0 | 0 | 60,814 | Withhold |
| Bridge Builder Trust | 0 | 0 | 0 | 57,984 | Withhold |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 44,900 | Withhold |
| RBB FUND, INC. | 33,621 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).
Combines 8 wordings of this item as funds reported it.
91% Approved · of votes cast
Prior year: 88.0% for (June 5, 2024 meeting) ▲ 2.8 pts
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.
Allogene Therapeutics, Inc.’s own tally for this item (“2. Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers”): 139,947,868 for, 14,233,309 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Approval, on an Advisory Basis, of the Compensation of the Company's Named Executive Officers The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement for the Annual Meeting.”
Support: 91% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 12,265,330 | 0 | 0 | Against |
| Vanguard | 5,033,780 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,096,572 | 0 | 0 | 0 | For |
| BlackRock | 2,062,716 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 867,250 | 0 | 0 | 0 | For |
| JPMorgan | 682,959 | 0 | 0 | 0 | For |
| Equitable | 436,753 | 0 | 0 | 0 | For |
| Charles Schwab | 428,818 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 273,875 | 0 | 0 | 0 | For |
| Fidelity | 263,240 | 0 | 0 | 0 | For |
| Lincoln Financial | 248,551 | 0 | 0 | 0 | For |
| Global X | 241,564 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 146,779 | 0 | 0 | 0 | For |
| Zacks Trust | 137,161 | 0 | 0 | 0 | For |
| State Street | 120,441 | 9 | 0 | 0 | For |
| AIG/SunAmerica | 96,500 | 0 | 0 | 0 | For |
| John Hancock | 92,113 | 0 | 0 | 0 | For |
| Northern Trust | 76,818 | 0 | 0 | 0 | For |
| Pacific Life | 68,912 | 0 | 0 | 0 | For |
| ETF Series Solutions | 68,858 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 60,814 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 57,984 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 44,900 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 33,621 | 0 | 0 | 0 | For |
Fund voting reports, all 46 managers: 16,588,976 for, 12,284,862 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 0 | 12,265,360 | 0 | 0 | Against |
| Lynx1 Capital Management LP | 11,057,009 | 0 | 0 | 0 | For |
| Citadel | 9,227,602 | 0 | 0 | 0 | For |
| BlackRock | 5,465,783 | 115,146 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 4,879,140 | 0 | 0 | 0 | For |
| T. Rowe Price | 4,170,069 | 0 | 0 | 0 | For |
| Frazier Life Sciences Management, L.P. | 3,868,750 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,785,168 | 53,987 | 0 | 0 | For |
| Woodline Partners LP | 3,709,357 | 0 | 0 | 0 | For |
| Foresite Capital Management VI LLC | 3,448,275 | 0 | 0 | 0 | For |
| Wildcat Capital Management, LLC | 0 | 0 | 2,920,787 | 0 | Abstain |
| JPMorgan | 2,890,404 | 0 | 0 | 0 | For |
| Vida Ventures Advisors, LLC | 1,798,163 | 0 | 0 | 0 | For |
| DAFNA Capital Management LLC | 1,380,118 | 0 | 0 | 0 | For |
| State Street | 1,361,154 | 9 | 0 | 0 | For |
| GILEAD SCIENCES, INC. | 1,156,689 | 0 | 0 | 0 | For |
| Aberdeen | 867,250 | 0 | 0 | 0 | For |
| BBR PARTNERS, LLC | 798,899 | 0 | 0 | 0 | For |
| TPG GP A, LLC | 675,000 | 0 | 0 | 0 | For |
| Northern Trust | 572,387 | 0 | 0 | 0 | For |
| Charles Schwab | 428,841 | 0 | 0 | 0 | For |
| Cerity Partners LLC | 414,499 | 0 | 0 | 0 | For |
| ZACKS INVESTMENT MANAGEMENT | 319,950 | 0 | 0 | 0 | For |
| Mitsubishi UFJ Asset Management Co., Ltd. | 267,336 | 0 | 0 | 0 | For |
| Moloney Securities Asset Management, LLC | 265,000 | 0 | 0 | 0 | For |
Institutional-manager reports, all 109 managers: 65,175,172 for, 12,535,929 against, 2,920,787 abstained. Showing the 25 largest; every one is in the interactive database (link above).
99.8% Approved · of votes cast
Prior year: 99.1% for (June 5, 2024 meeting) ▲ 0.7 pts
Description as filed by funds: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.
Allogene Therapeutics, Inc.’s own tally for this item (“3. Ratification of the Selection of Independent Registered Public Accounting Firm”): 190,111,256 for, 414,604 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 47 asset managers below reported 28,873,838 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Capital Group | 12,265,330 | 0 | 0 | 0 | For |
| Vanguard | 5,033,780 | 0 | 0 | 0 | For |
| T. Rowe Price | 3,096,572 | 0 | 0 | 0 | For |
| BlackRock | 2,062,716 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 1,785,270 | 0 | 0 | 0 | For |
| Aberdeen | 867,250 | 0 | 0 | 0 | For |
| JPMorgan | 682,959 | 0 | 0 | 0 | For |
| Equitable | 436,753 | 0 | 0 | 0 | For |
| Charles Schwab | 428,818 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 273,875 | 0 | 0 | 0 | For |
| Fidelity | 263,240 | 0 | 0 | 0 | For |
| Lincoln Financial | 248,551 | 0 | 0 | 0 | For |
| Global X | 241,564 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 146,779 | 0 | 0 | 0 | For |
| Zacks Trust | 137,161 | 0 | 0 | 0 | For |
| State Street | 120,450 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 96,500 | 0 | 0 | 0 | For |
| John Hancock | 92,113 | 0 | 0 | 0 | For |
| Northern Trust | 76,818 | 0 | 0 | 0 | For |
| Pacific Life | 68,912 | 0 | 0 | 0 | For |
| ETF Series Solutions | 68,858 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 60,814 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 57,984 | 0 | 0 | 0 | For |
| Blackstone Alternative Investment Funds | 44,900 | 0 | 0 | 0 | For |
| RBB FUND, INC. | 33,621 | 0 | 0 | 0 | For |
Showing the 25 largest of 47 asset managers. All 47 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 218,598,262 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 5.61% |
| 2 | Vanguard | 2.30% |
| 3 | T. Rowe Price | 1.42% |
| 4 | BlackRock | 0.94% |
| 5 | PRIMECAP Odyssey Funds | 0.82% |
| 6 | Aberdeen | 0.40% |
| 7 | JPMorgan | 0.31% |
| 8 | Equitable | 0.20% |
| 9 | Charles Schwab | 0.20% |
| 10 | Columbia Threadneedle | 0.13% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Capital Group | 5.61% |
| 2 | Lynx1 Capital Management LP | 5.06% |
| 3 | Citadel | 4.22% |
| 4 | BlackRock | 2.55% |
| 5 | PRIMECAP MANAGEMENT CO/CA/ | 2.23% |
| 6 | T. Rowe Price | 1.91% |
| 7 | Frazier Life Sciences Management, L.P. | 1.77% |
| 8 | Goldman Sachs | 1.76% |
| 9 | Woodline Partners LP | 1.70% |
| 10 | Foresite Capital Management VI LLC | 1.58% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Pfizer Inc. | 22,032,040 | 10.08% | Schedule 13D, filed February 13, 2026 |
| TPG GP A, LLC | 18,716,306 | 8.56% | Proxy statement (DEF 14A), proxy filed April 30, 2025 |
| BlackRock | 17,932,906 | 8.20% | Form 13F, quarter ended March 31, 2025 |
| Arie Belldegrun, M.D. | 13,466,383 | 6.16% | Schedule 13G, filed May 13, 2026 |
| David D. Chang, M.D., Ph.D. | 12,297,354 | 5.63% | Schedule 13G, filed May 13, 2026 |
| David Chang, M.D., Ph.D. | 11,043,100 | 5.05% | Proxy statement (DEF 14A), proxy filed April 30, 2025 |
| Citadel Advisors | 10,302,629 | 4.71% | Form 13F, quarter ended March 31, 2025 |
| Vanguard Group | 8,067,553 | 3.69% | Form 13F, quarter ended March 31, 2025 |
| FMR (Fidelity) | 7,394,162 | 3.38% | Form 13F, quarter ended March 31, 2025 |
| Kenneth Griffin | 6,855,120 | 3.14% | Schedule 13G, filed May 15, 2026 |
Percentages above are of 218,598,262 shares outstanding, as reported by Allogene Therapeutics, Inc. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Allogene Therapeutics, Inc.'s shareholder meeting held June 18, 2025, in the 2024-2025 proxy season, 141 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 824 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Allogene Therapeutics, Inc.'s filing reports the proposal as approved, with 91% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Allogene Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 23, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Allogene Therapeutics, Inc.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Allogene Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “Allogene Therapeutics (ALLO) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/allogene-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.